Y-MABS THERAPEUTICS INC (YMAB) Stock News
NASDAQ:YMAB - Nasdaq - US9842411095 - Common Stock - Currency: USD
YMAB Latest News, Press Relases and Analysis
Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates
Qiagen (QGEN) delivered earnings and revenue surprises of 10% and 4.18%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: QGEN
Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage...
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
PRINCETON, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage...
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q1 Earnings Expected to Decline
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: ACAD
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline
YmAbs Therapeutics (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: FOLD
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting
NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments ...
Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
Naxitamab demonstrated clinically meaningful efficacy with manageable safety in patients with relapsed/refractory high-risk neuroblastoma and residual...
Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...
Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...
Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities
Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial...
Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...
Y-mAbs Provides Strategic Business Update and 2025 Priorities
Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the commercial...
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
NEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...
Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...
Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
Reported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024Entered into exclusive license and distribution agreement with...
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan
NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...
Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast
NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...
Y-mAbs to Participate in Upcoming Investor Conferences in October
NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...